The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
Open accessAbstract
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in psoriasis, psoriatic arthropathies, and Behçet's syndrome. In March 2014, the US Food and Drug Administration approved apremilast for the treatment of adult patients with active psoriatic arthritis. The properties of apremilast were evaluated to determine its specificity, effects on intracellular signaling, gene and protein expression, and in vivo pharmacology using models of innate and adaptive immunity. Apremilast inhibited PDE4 isoforms from all four sub-families (A1A, B1, B2, C1, and D2), with IC50 values in the range of 10 to 100 nM. Apremilast did not significantly inhibit other PDEs, kinases, enzymes, or receptors. While both apremilast and thalidomide share a phthalimide ring structure, apremilast lacks the glutarimide ring and thus fails to bind to cereblon, the target of thalidomide action. In monocytes and T cells, apremilast elevated intracellular cAMP and induced phosphorylation of the protein kinase A substrates CREB and activating transcription factor-1 while inhibiting NF-κB transcriptional activity, resulting in both up- and down-regulation of several genes induced via TLR4. Apremilast reduced interferon-α production by plasmacytoid dendritic cells and inhibited T-cell cytokine production, but had little effect on B-cell immunoglobulin secretion. In a transgenic T-cell and B-cell transfer murine model, apremilast (5mg/kg/day p.o.) did not affect clonal expansion of either T or B cells and had little or no effect on their expression of activation markers. The effect of apremilast on innate immunity was tested in the ferret lung neutrophilia model, which allows monitoring of the known PDE4 inhibitor gastrointestinal side effects (nausea and vomiting). Apremilast significantly inhibited lung neutrophilia at 1mg/kg, but did not induce significant emetic reflexes at doses <30 mg/kg. Overall, the pharmacological effects of apremilast are consistent with those of a targeted PDE4 inhibitor, with selective effects on innate immune responses and a wide therapeutic index compared to its gastrointestinal side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
Conti, M., & Beavo, J. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060305.150444 · Cited by 1,183
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Self-citationCorral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Self-citationCorral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
Self-citationMammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions
Francis, S. H., Blount, M. A., & Corbin, J. D. (2011) · Physiological Reviews · doi:10.1152/physrev.00030.2010 · Cited by 639
Keynote review: Phosphodiesterase-4 as a therapeutic target
Houslay, M. D., Schafer, P., & Zhang, K. Y. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03622-6 · Cited by 635
Self-citationGuidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Lim, H. W., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.027 · Cited by 558
Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P., & Bartlett, J. B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4405 · Cited by 440
Self-citationApremilast mechanism of action and application to psoriasis and psoriatic arthritis
Schafer, P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.001 · Cited by 439
Self-citationUnderpinning compartmentalised cAMP signalling through targeted cAMP breakdown
Houslay, M. D. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.09.007 · Cited by 430
Regulatory B cells as inhibitors of immune responses and inflammation
Bouaziz, J., Yanaba, K., & Tedder, T. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00661.x · Cited by 425
Cyclic AMP: Master Regulator of Innate Immune Cell Function
Serezani, C. H., Ballinger, M. N., Aronoff, D. M., & Peters-Golden, M. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0091tr · Cited by 415
Schafer, P., Parton, A., Gandhi, A., Capone, L., Adams, M., Wu, L., Bartlett, J., Loveland, M., Gilhar, A., Cheung, Y., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00559.x · Cited by 406
Self-citationIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
Krueger, J. G., Fretzin, S., Suárez-Fariñas, M., Haslett, P. A., Phipps, K. M., Cameron, G. S., McColm, J., Katcherian, A., Cueto, I., White, T., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.024 · Cited by 383
Ollivier, V., Parry, G. C. N., Cobb, R. R., de Prost, D., & Mackman, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20828 · Cited by 336
Parry, G. C., & Mackman, N. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.11.5450 · Cited by 332
Houslay, M. D., Baillie, G. S., & Maurice, D. H. (2007) · Circulation Research · doi:10.1161/01.res.0000261934.56938.38 · Cited by 317
Papp, K., Cather, J. C., Rosoph, L., Sofen, H., Langley, R. G., Matheson, R. T., Hu, C., & Day, R. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60642-4 · Cited by 282
Schett, G., Wollenhaupt, J., Papp, K., Joos, R., Rodrigues, J. F., Vessey, A. R., Hu, C., Stevens, R., & de Vlam, K. L. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34627 · Cited by 205
Man, H.-W., Schafer, P., Wong, L. M., Patterson, R. T., Corral, L. G., Raymon, H., Blease, K., Leisten, J., Shirley, M. A., Tang, Y., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900210d · Cited by 183
Self-citationCyclic Nucleotide Phosphodiesterases in Health and Disease
(2006) · CRC Press eBooks · doi:10.1201/9781420020847 · Cited by 173
Inhibition of the NF‐κB transcriptional activity by protein kinase A
Takahashi, N., Tetsuka, T., Uranishi, H., & Okamoto, T. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03157.x · Cited by 170
McCann, F. E., Palfreeman, A. C., Andrews, M. R., Perocheau, D. P. B., Inglis, J. J., Schafer, P. H., Feldmann, M., Williams, R. O., & Brennan, F. M. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3041 · Cited by 134
Self-citationMcLaughlin, M. M., Cieslinski, L. B., Burman, M., Torphy, T. J., & Livi, G. P. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53275-0 · Cited by 128
Barber, R., Baillie, G. S., Bergmann, R., Shepherd, M. C., Sepper, R., Houslay, M. D., & Heeke, G. V. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00384.2003 · Cited by 121
Jiménez, J. L., Punzón, C., Navarro, J., Muñoz‐Fernández, M. Á., & Fresno, M. (2001) · PubMed · Cited by 115
Zaba, L. C., Fuentes‐Duculan, J., Eungdamrong, N. J., Johnson-Huang, L. M., Nograles, K. E., White, T. R., Pierson, K. C., Lentini, T., Suárez‐Fariñas, M., Lowes, M. A., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.03.018 · Cited by 106
Gottlieb, A. B., Matheson, R. T., Menter, A., Leonardi, C. L., Day, R. M., Hu, C., Schafer, P. H., & Krueger, J. G. (2013) · PubMed · Cited by 76
Self-citationJiménez, J. L., Punzón, C., Navarro, J., Muñoz‐Fernández, M. Á., & Fresno, M. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29287-9 · Cited by 68
Thalidomide analogs and PDE4 inhibition
Muller, G. W., Shire, M. G., Wong, L. M., Corral, L. G., Patterson, R. T., Chen, Y., & Stirling, D. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00475-2 · Cited by 67
Self-citationTenor, H., Hatzelmann, A., Beume, R., Lahu, G., Zech, K., & Bethke, T. D. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_3 · Cited by 46
Phosphodiesterase inhibitors in inflammatory bowel disease
Salari, P., & Abdollahi, M. R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.658915 · Cited by 40
Huston, E., Houslay, T. M., Baillie, G. S., & Houslay, M. D. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340504 · Cited by 36
Molostvov, G., Morris, A. G., Rose, P. E., Basu, S., & Muller, G. W. (2004) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04777.x · Cited by 18
Self-citationUnbiased identification of substrates for the Epac1-inducible E3 ubiquitin ligase component SOCS-3
Williams, J. J. L., & Palmer, T. M. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110629 · Cited by 15
Cited by
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
Enthesitis: from pathophysiology to treatment
Schett, G., Lories, R. J., D'Agostino, M.-A., Elewaut, D., Kirkham, B., Soriano, E. R., & McGonagle, D. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.188 · Cited by 503
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis
Simpson, E. L., Imafuku, S., Poulin, Y., Ungar, B., Zhou, L., Malik, K., Wen, H.-C., Xu, H., Estrada, Y. D., Peng, X., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.10.043 · Cited by 120
Kailasam, V., Malani, M., & Nirmal, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126162 · Cited by 3
Metadata
- Authors
- Schafer, P. H., Parton, A., Capone, L., Cedzik, D., Brady, H., Evans, J. F., Man, H.-W., Muller, G. W., Stirling, D. I., & Chopra, R.
- Venue
- Cellular Signalling
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 26
- Issue
- 9
- Pages
- 2016-2029
- ISSN
- 0898-6568 (ISSN-L)
- OpenAlex
- W1996677952
- Cited by
- 310
- References
- 38
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.